- SB 11285 Shows Potent and Durable, Immune-Mediated Anti-Tumor Activity in Both Lymphoma and Colon Cancer Animal Models
HOPKINTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH) announced today that an abstract regarding its lead STING agonist candidate was published at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 – 6th in Chicago, IL. The Spring Bank abstract was titled “Preclinical Studies of SB 11285, a Novel STING (STimulator of INterferon Genes) Agonist for Immuno-Oncology.” The abstract includes results from the efficacy studies of SB 11285 in the syngeneic mouse models of A20 lymphoma and CT26 colon cancer, which both showed very potent and highly-durable, immune-mediated anti-tumor activity. This abstract is available on the Spring Bank Pharmaceuticals website at www.springbankpharm.com/publications/.
“We continue to be impressed with the preclinical study results of our novel, next-generation STING agonist compound, SB 11285, as we advance its development with the goal to potentially submit an Investigational New Drug (IND) application and/or a Clinical Trial Application (CTA) for the first human clinical trials of SB 11285 in certain cancers in 2018,” stated Dr. Radhakrishnan (Kris) Iyer, Ph.D., chief scientific officer of Spring Bank Pharmaceuticals.
Spring Bank has also conducted additional preclinical studies of SB 11285 and other analogs from its proprietary STING platform using multiple routes of administration in the A20 lymphoma, orthotopic 4T1 breast cancer and CT26 colon cancer syngeneic mouse models. These studies demonstrated the induction of immune memory and abscopal anti-tumor activity, upon intra-tumoral administration of SB 11285 in the A20 lymphoma model. In addition, SB 11285 demonstrated dose-dependent, potent tumor growth inhibition and durable anti-tumor response upon intra-tumoral, intraperitoneal, and intravenous routes of administration in the CT26 colon cancer syngeneic mouse model. In the orthotopic 4T1 breast cancer model, intraperitoneal administration of SB 11285 resulted in significant inhibition of primary tumor growth, as well as inhibition of tumor metastasis.
“These preclinical studies demonstrate the potential for both intra-tumoral and systemic administration of SB 11285 to target a variety of tumors, which could be particularly relevant for use in combination with other therapeutic modalities. We also believe that certain compounds in our proprietary STING platform have specific structural, biochemical and pharmaceutical attributes that could be engineered for conjugation with other agents for targeted delivery and for additive and/or synergistic anti-cancer activity. We look forward to presenting additional preclinical study results for SB 11285 at various scientific conferences later this year and in 2018,” stated Dr. Iyer.
About SB 11285
Spring Bank’s lead immunotherapeutic product candidate, SB 11285, is a novel small molecule nucleic acid hybrid (SMNH) compound being developed as a potential treatment for certain cancers. SB 11285 is a next-generation STING (STimulator of INterferon Genes) agonist currently in preclinical development. Spring Bank is developing SB 11285 to be delivered by multiple routes of administration including intra-tumoral, intravenous, and potentially orally. Spring Bank is advancing the development of SB 11285 with the plan to initiate its first clinical trial in 2018.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway. For more information, please visit www.springbankpharm.com.
Forward-Looking Statements
Statements in this press release about Spring Bank’s future expectations, plans and prospects, including, but not limited to, statements about the company’s anticipated timelines for submitting an IND and/or CTA for SB 11285 and for presenting additional preclinical study results for SB 11285, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis, or at all; whether the results of such trials will warrant submission for approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether Spring Bank’s product candidates will receive approval from regulatory agencies on a timely basis or at all; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Spring Bank’s Annual Report on Form 10-K for the year ended December 31, 2016, which was filed with the Securities and Exchange Commission (SEC) on February 14, 2017, and in other filings Spring Bank makes with the SEC from time to time.
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof. Spring Bank anticipates that subsequent events and developments will cause Spring Bank’s views to change. However, while Spring Bank may elect to update these forward-looking statements at some point in the future, Spring Bank specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spring Bank’s views as of any date subsequent to the date hereof.
Source: Spring Bank Pharmaceuticals
Contact: Spring Bank Pharmaceuticals, Inc. Jonathan Freve Chief Financial Officer (508) 473-5993 jfreve@springbankpharm.com
